小肠细菌过度生长的呼气试验：一种富集肠易激综合征患者中利福昔明应答者的方法？ - Suppr

Breath Testing for Small Intestinal Bacterial Overgrowth: A Means to Enrich Rifaximin Responders in IBS Patients?

作者信息

Gupta Amit, Chey William D

机构信息

Department of Internal Medicine, Division of Gastroenterology, University of Michigan Health System, Ann Arbor, Michigan, USA.

出版信息

Am J Gastroenterol. 2016 Mar;111(3):305-6. doi: 10.1038/ajg.2016.32. Epub 2016 Mar 1.

DOI:10.1038/ajg.2016.32

PMID:26925880

Abstract

摘要

相似文献

Breath Testing for Small Intestinal Bacterial Overgrowth: A Means to Enrich Rifaximin Responders in IBS Patients?小肠细菌过度生长的呼气试验：一种富集肠易激综合征患者中利福昔明应答者的方法？

Am J Gastroenterol. 2016 Mar;111(3):305-6. doi: 10.1038/ajg.2016.32. Epub 2016 Mar 1.

A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients.一项关于联合使用乳果糖氢呼气试验与闪烁扫描法口盲肠转运试验诊断肠易激综合征（IBS）患者小肠细菌过度生长的方法学及临床有效性的研究。

Neurogastroenterol Motil. 2014 Jun;26(6):794-802. doi: 10.1111/nmo.12331. Epub 2014 Mar 18.

Small intestinal bacterial overgrowth as a cause for irritable bowel syndrome: guilty or not guilty?小肠细菌过度生长作为肠易激综合征的一个病因：有罪还是无罪？

Curr Opin Gastroenterol. 2017 May;33(3):196-202. doi: 10.1097/MOG.0000000000000348.

Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome which are improved by rifaximin. A pilot study.小肠细菌过度生长在肠易激综合征中产生症状，利福昔明可改善这些症状。一项初步研究。

Rom J Intern Med. 2013 Jul-Dec;51(3-4):143-7.

High dosage rifaximin for the treatment of small intestinal bacterial overgrowth.高剂量利福昔明治疗小肠细菌过度生长

Aliment Pharmacol Ther. 2007 Apr 1;25(7):781-6. doi: 10.1111/j.1365-2036.2007.03259.x.

Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin.小肠细菌过度生长与肠易激综合征相关症状：利福昔明的应用经验

World J Gastroenterol. 2009 Jun 7;15(21):2628-31. doi: 10.3748/wjg.15.2628.

Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.综述：利福昔明治疗腹泻型肠易激综合征的潜在作用机制。

Aliment Pharmacol Ther. 2016 Jan;43 Suppl 1:37-49. doi: 10.1111/apt.13437.

Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome.利福昔明治疗儿童肠易激综合征合并小肠细菌过度生长。

Eur Rev Med Pharmacol Sci. 2013 May;17(10):1314-20.

Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota.利福昔明对感染后肠易激综合征小鼠模型的有益作用超出了肠道微生物群。

J Gastroenterol Hepatol. 2018 Feb;33(2):443-452. doi: 10.1111/jgh.13841.

Microscopic colitis and small intestinal bacterial overgrowth--diagnosis behind the irritable bowel syndrome?显微镜下结肠炎与小肠细菌过度生长——肠易激综合征背后的诊断？

Rev Med Chir Soc Med Nat Iasi. 2012 Jul-Sep;116(3):766-72.

引用本文的文献

Effect of Dietary Paeoniae Radix Alba Extract on the Growth Performance, Nutrient Digestibility and Metabolism, Serum Biochemistry, and Small Intestine Histomorphology of Raccoon Dog During the Growing Period.日粮白芍提取物对生长育肥期貉生长性能、养分消化代谢、血清生化指标及小肠组织形态的影响

Front Vet Sci. 2022 Apr 4;9:839450. doi: 10.3389/fvets.2022.839450. eCollection 2022.

Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome - An Update.小肠细菌过度生长与肠易激综合征——最新进展

Front Psychiatry. 2020 Jul 10;11:664. doi: 10.3389/fpsyt.2020.00664. eCollection 2020.

Value-based Pricing for Rifaximin Increases Access of Patients With Irritable Bowel Syndrome With Diarrhea to Therapy.利福昔明基于价值的定价增加了腹泻型肠易激综合征患者获得治疗的机会。

Clin Gastroenterol Hepatol. 2019 Dec;17(13):2687-2695.e11. doi: 10.1016/j.cgh.2019.02.039. Epub 2019 Mar 1.

The gut microbiome and irritable bowel syndrome.肠道微生物群与肠易激综合征

F1000Res. 2018 Jul 9;7. doi: 10.12688/f1000research.14592.1. eCollection 2018.

Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth.系统评价与荟萃分析：利福昔明治疗小肠细菌过度生长有效且安全。

Aliment Pharmacol Ther. 2017 Mar;45(5):604-616. doi: 10.1111/apt.13928. Epub 2017 Jan 12.

Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders.功能性肠病中肠道微生物群的治疗性调节

J Neurogastroenterol Motil. 2017 Jan 30;23(1):9-19. doi: 10.5056/jnm16124.

It is Time to Re-Think the Role of Small Intestinal Bacterial Overgrowth in IBS Patients.是时候重新思考小肠细菌过度生长在肠易激综合征患者中的作用了。

Am J Gastroenterol. 2016 Sep;111(9):1364. doi: 10.1038/ajg.2016.290.

Use of rifaximin in gastrointestinal and liver diseases.利福昔明在胃肠道和肝脏疾病中的应用。

World J Gastroenterol. 2016 Aug 7;22(29):6638-51. doi: 10.3748/wjg.v22.i29.6638.

本文引用的文献

Breath testing for small intestinal bacterial overgrowth: maximizing test accuracy.小肠细菌过度生长的呼吸试验：最大限度提高试验准确性。

Clin Gastroenterol Hepatol. 2014 Dec;12(12):1964-72; quiz e119-20. doi: 10.1016/j.cgh.2013.09.055. Epub 2013 Oct 1.

The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis.利福昔明治疗肠易激综合征的疗效和安全性：系统评价和荟萃分析。

Am J Gastroenterol. 2012 Jan;107(1):28-35; quiz 36. doi: 10.1038/ajg.2011.355. Epub 2011 Nov 1.

Rifaximin therapy for patients with irritable bowel syndrome without constipation.利福昔明治疗无便秘型肠易激综合征患者。

N Engl J Med. 2011 Jan 6;364(1):22-32. doi: 10.1056/NEJMoa1004409.

Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.利福昔明：一种用于治疗肠道疾病的胃肠道选择性抗生素。

Curr Opin Gastroenterol. 2010 Jan;26(1):17-25. doi: 10.1097/MOG.0b013e328333dc8d.

Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference.胃肠疾病中H2呼气试验的方法与指征：罗马共识会议

Aliment Pharmacol Ther. 2009 Mar 30;29 Suppl 1:1-49. doi: 10.1111/j.1365-2036.2009.03951.x.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Breath Testing for Small Intestinal Bacterial Overgrowth: A Means to Enrich Rifaximin Responders in IBS Patients?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献